Intensity Therapeutics (INTS) Operating Expenses (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Operating Expenses came in at $2.5 million in Q1 2026, down 25.57% YoY from $3.4 million in Q1 2025, and down 19.55% on a QoQ basis from $3.1 million in Q4 2025.
Intensity Therapeutics (INTS) Operating Expenses (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Operating Expenses data on file, last reported at $2.5 million in Q1 2026.
- Quarterly Operating Expenses fell 25.57% year-over-year to $2.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.1 million (down 27.12% YoY) and the FY2025 annual result came in at $12.0 million, down 27.81% from the prior year.
- Operating Expenses declined to $2.5 million in Q1 2026, from $3.1 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $5.1 million in Q2 2024 to a low of $1.2 million in Q2 2023.
- A 5-year average of $2.8 million and a median of $2.7 million in 2025 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2024 — Operating Expenses surged 315.15% — and 2025, when it slumped 46.64%.
- Tracing INTS's Operating Expenses over 5 years: stood at $1.5 million in 2022, then surged by 127.43% to $3.4 million in 2023, then declined by 4.45% to $3.2 million in 2024, then decreased by 1.97% to $3.1 million in 2025, then decreased by 19.55% to $2.5 million in 2026.
- The last three Operating Expenses figures came in at $2.5 million (Q1 2026), $3.1 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - | 3.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.08 Mn |
| Mar 31, 2026 | 2.53 Mn |
| Dec 31, 2025 | 3.14 Mn |
| Sep 30, 2025 | 2.73 Mn |
| Jun 30, 2025 | 2.71 Mn |
| Mar 31, 2025 | 3.39 Mn |
| Dec 31, 2024 | 3.20 Mn |
| Sep 30, 2024 | 3.57 Mn |
| Jun 30, 2024 | 5.07 Mn |
| Mar 31, 2024 | 4.74 Mn |
| Dec 31, 2023 | 3.35 Mn |
| Sep 30, 2023 | 2.49 Mn |
| Jun 30, 2023 | 1.22 Mn |
| Mar 31, 2023 | 1.25 Mn |
| Dec 31, 2022 | 1.47 Mn |
| Sep 30, 2022 | 1.77 Mn |
| Jun 30, 2022 | 1.93 Mn |